GIAPREZA Drug Patent Profile
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Which patents cover Giapreza, and what generic alternatives are available?
Giapreza is a drug marketed by La Jolla Pharma and is included in one NDA. There are ten patents protecting this drug and one Paragraph IV challenge.
This drug has forty-four patent family members in twenty-three countries.
The generic ingredient in GIAPREZA is angiotensin ii acetate. There are five drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the angiotensin ii acetate profile page.
DrugPatentWatch® Generic Entry Outlook for Giapreza
Giapreza was eligible for patent challenges on December 21, 2021.
There is one Paragraph IV patent challenge for this drug. This may lead to patent invalidation or a license for generic production.
Indicators of Generic Entry
Summary for GIAPREZA
International Patents: | 44 |
US Patents: | 10 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 53 |
Clinical Trials: | 6 |
Patent Applications: | 7,510 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for GIAPREZA |
What excipients (inactive ingredients) are in GIAPREZA? | GIAPREZA excipients list |
DailyMed Link: | GIAPREZA at DailyMed |


Recent Clinical Trials for GIAPREZA
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
National Center for Advancing Translational Science (NCATS) | Phase 4 |
University of New Mexico | Phase 4 |
University of California, Los Angeles | Phase 2 |
Pharmacology for GIAPREZA
Drug Class | Vasoconstrictor |
Physiological Effect | Vasoconstriction |
Anatomical Therapeutic Chemical (ATC) Classes for GIAPREZA
Paragraph IV (Patent) Challenges for GIAPREZA
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
GIAPREZA | Injection | angiotensin ii acetate | 2.5 mg/mL | 209360 | 1 | 2021-12-21 |
US Patents and Regulatory Information for GIAPREZA
GIAPREZA is protected by fifteen US patents and one FDA Regulatory Exclusivity.
Patents protecting GIAPREZA
Angiotensin II alone or in combination for the treatment of hypotension
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: MAINTAINING MEAN ARTERIAL PRESSURE OF ABOUT 65 MMHG OR ABOVE WITH ABOUT 1 NG/KG/MIN TO ABOUT 40 NG/KG/MIN ANGIOTENSIN II IN HYPOTENSIVE PATIENTS TREATED WITH VASOPRESSIN OR A VASOPRESSIN ANALOGUE AND REDUCING VASOPRESSIN OR VASOPRESSIN ANALOGUE USE
Method of treating low blood pressure
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATING HYPOTENSION WITH ABOUT 20 NG/KG/MIN TO ABOUT 40 NG/KG/MIN ANGIOTENSIN II IN A HUMAN SUBJECT HAVING SEPTIC SHOCK
Angiotensin II alone or in combination for the treatment of hypotension
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATING LOW BLOOD PRESSURE WITH ANGIOTENSIN II AT AN INITIAL RATE OF ABOUT 20 NG/KG/MIN AND TITRATING DOWN TO ACHIEVE AND/OR MAINTAIN A MAP OF ABOUT 65 MM HG OR ABOVE
Method of treating low blood pressure
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATING LOW BLOOD PRESSURE WITH ANGIOTENSIN II WITH AN INITIAL RATE OF ABOUT 5 NG/KG/MIN TO ABOUT 20 NG/KG/MIN IN A SUBJECT HAVING REFRACTORY HYPOTENSION OR SEVERE HYPOTENSION, AND TITRATING THE RATE UP
Method of treating low blood pressure
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATING LOW BLOOD PRESSURE WITH ANGIOTENSIN II WITH AN INITIAL RATE OF ABOUT 5 NG/KG/MIN TO ABOUT 20 NG/KG/MIN IN A SUBJECT HAVING REFRACTORY HYPOTENSION OR SEVERE HYPOTENSION
Method of treating low blood pressure
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: INCREASING BLOOD PRESSURE WITH A RATE OF ABOUT 20 NG/KG/MIN TO ABOUT 40 NG/KG/MIN ANGIOTENSIN II IN A HUMAN SUBJECT HAVING SEPTIC SHOCK
Method of treating low blood pressure
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: INCREASING BLOOD PRESSURE WITH AN INITIAL RATE OF ABOUT 20 NG/KG/MIN ANGIOTENSIN II IN A HUMAN SUBJECT HAVING SEPTIC SHOCK, AND TITRATING THE RATE UP.
Angiotensin II alone or in combination for the treatment of hypotension
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATING SEPTIC SHOCK WITH ANGIOTENSIN II
Angiotensin II alone or in combination for the treatment of hypotension
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATING DISTRIBUTIVE SHOCK WITH ANGIOTENSIN II
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATING HYPOTENSION WITH ANGIOTENSIN II IN A PATIENT RECEIVING AN ANGIOTENSIN CONVERTING ENZYME INHIBITOR
Angiotensin II alone or in combination for the treatment of hypotension
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATING HIGH OUTPUT SHOCK WITH ANGIOTENSIN II BY INCREASING MEAN ARTERIAL PRESSURE IN PATIENTS TREATED WITH CATECHOLAMINES AND REDUCING CATECHOLAMINE USE
Angiotensin II alone or in combination for the treatment of hypotension
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: MAINTAINING MEAN ARTERIAL PRESSURE OF ABOUT 65 MMHG OR HIGHER WITH ANGIOTENSIN II IN SHOCK PATIENTS TREATED WITH CATECHOLAMINES AND REDUCING CATECHOLAMINE USE
Method of treating low blood pressure
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATING REFRACTORY HYPOTENSION WITH ABOUT 20 NG/KG/MIN ANGIOTENSIN II IN A PATIENT RECEIVING VASOPRESSOR
Method of treating low blood pressure
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATING REFRACTORY HYPOTENSION WITH ABOUT 20 NG/KG/MIN ANGIOTENSIN II IN A PATIENT RECEIVING VASOPRESSOR
Method of treating low blood pressure
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATING REFRACTORY HYPOTENSION WITH ABOUT 5 NG/KG/MIN TO ABOUT 20 NG/KG/MIN ANGIOTENSIN II IN A PATIENT RECEIVING VASOPRESSOR
FDA Regulatory Exclusivity protecting GIAPREZA
NEW CHEMICAL ENTITY
Exclusivity Expiration: ⤷ Try a Trial
International Patents for GIAPREZA
See the table below for patents covering GIAPREZA around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Serbia | 59804 | ANGIOTENZIN II U KOMBINACIJI ZA LEČENJE HIPOTENZIJE (ANGIOTENSIN II IN COMBINATION FOR THE TREATMENT OF HYPOTENSION) | ⤷ Try a Trial |
Japan | 2019214610 | 低血圧治療のための単独または併用使用されるアンギオテンシンII (ANGIOTENSIN II ALONE OR IN COMBINATION FOR TREATMENT OF HYPOTENSION) | ⤷ Try a Trial |
Japan | 6824739 | ⤷ Try a Trial | |
China | 112546197 | 血管紧张素II单独或以组合方式用于治疗低血压 (Angiotensin ll alone or in combination for the treatment of hypotension) | ⤷ Try a Trial |
South Korea | 20220028125 | 저혈압의 치료를 위한 안지오텐신 II 단독 또는 조합 (II ANGIOTENSIN II ALONE OR IN COMBINATION FOR THE TREATMENT OF HYPOTENSION) | ⤷ Try a Trial |
South Korea | 102399383 | ⤷ Try a Trial | |
Taiwan | 201733610 | Methods for administering angiotensin II | ⤷ Try a Trial |
>Country | >Patent Number | >Title | >Estimated Expiration |